Washington, D.C. (The Adobo Chronicles) – The. U.S. Food and Drug Administration (FDA) today announced the approval of a new pill that would cure selfitis, the obsessive-compulsive urge to take photos of one’s self and posting them on social media.

Recently, the American Psychiatric Association (APA) officially classified selfie-taking as a mental disorder with three levels of the disease: borderline, acute and chronic.

The FDA announcement unveiled three color-coded pills that doctors can prescribe to their patients: green for borderline, blue for acute and red for chronic selfitis. In clinical trials conducted prior to the FDA approval, the pills showed an efficacy rate of plus or minus three percent.

The new pills are similar to FDA-approved drugs that fall under the category of SSRI, or selective serotonin reuptake inhibitors, used to treat depression and anxiety. The new pills’ manufacturer, Actavis which recently acquired Forest Laboratories, said the new drug will be marketed under the brand name selpram . Forest Laboratories owns the brand name Celexa (citalopram) which is prescribed for depression.

The FDA announcement came as a huge relief to selfie addicts, a population that has grown to  almost 1 Billion worldwide. Equally, Facebook and Instagram users will be spared from the agony of having to deal with their friends’ selfies all too frequently posted on their walls.

Selpram will be available in the market starting this fall.